Weeks after Imara announced plans to discontinue the development of tovinontrinein for sickle cell disease, beta-thalassemia and heart failure indications, the company culled 83 percent of its workforce.

Teva Pharmaceutical Industries’ board of directors agreed to take a 50 percent pay cut.